Chunhui Han, PhD, discusses the potential feasibility of the integration of Gallium 68 PSMA-11 in biology-guided radiotherapy ...

Shubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2-positive biliary tract cancer ...

Joe DePinto, MBA, discusses some of the key challenges to equitable access to cell and gene therapies, especially in ...

A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety ...

Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.

In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive ...

Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node ...

Invikafusp alfa showed promise as a treatment option across a range of high tumor mutational burden cancers or virally ...

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate ...

During a Case-Based Roundtable® event, Omar Nadeem, MD, and participants reacted to data from the MonumenTAL-1 trial in the ...

Along with the Oncology Brothers, Paolo Tarantino, MD, provides an overview of the pPhase 3 EMERALD study, which evaluates the efficacy of elacestrant as a second-line treatment for ER+/HER2–- ...

Treatment with pimicotinib achieved a 54% objective response rate at 25 weeks vs 3.2% with placebo in patients with TGCT, ...